Can I Take Quercetin with Oral Micronized Progesterone (Prometrium)?

How Oral Micronized Progesterone Is Metabolized

Oral micronized progesterone is absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver before reaching systemic circulation. The dominant enzyme responsible for that conversion is CYP3A4, which oxidizes progesterone to several metabolites including 5-alpha-pregnane derivatives that carry their own sedative and neurosteroid activity. Prometrium prescribing information confirms that the bioavailability of oral micronized progesterone is substantially lower than that of parenteral forms precisely because of this first-pass effect. [1]

Why CYP3A4 Matters for Prometrium Users

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver and intestine, accounting for roughly 30 to 40% of all cytochrome P450-mediated drug metabolism. Inhibiting CYP3A4 slows the breakdown of substrates like progesterone, which can increase the area under the plasma concentration curve (AUC) for those substrates. A larger AUC means more progesterone exposure per dose.

For most women taking Prometrium at 100 mg or 200 mg nightly for endometrial protection, a modest AUC increase might manifest as heightened drowsiness the morning after dosing, more pronounced breast tenderness, or mild fluid retention. These are dose-dependent progesterone effects. They are generally not dangerous, but they are meaningful if a clinician is titrating the lowest effective dose.

What the Prescribing Label Says About CYP3A4 Inhibitors

The FDA-approved label for Prometrium specifically lists CYP3A4 inhibitors, including ketoconazole and grapefruit juice, as agents that can increase progesterone exposure. [1] The clinical instruction in the label is to use caution and to monitor for signs of progesterone excess when any known CYP3A4 inhibitor is co-administered. Quercetin is not named by brand in the label because it is a dietary supplement, not a prescription drug, but it acts through the same enzymatic pathway.

Quercetin's Effect on CYP3A4

Quercetin (3,3',4',5,7-pentahydroxyflavone) is a polyphenol flavonoid found in onions, apples, and capers. In supplement form it is sold at doses typically ranging from 250 mg to 1,000 mg per day, often marketed for its antihistamine, anti-inflammatory, and antioxidant properties.

In Vitro and Human Pharmacokinetic Evidence

A 2002 study by Xu and colleagues (Drug Metabolism and Disposition, PMID 11961093) demonstrated that quercetin inhibits CYP3A4 activity in human liver microsomes in a concentration-dependent manner, with an IC50 in the low micromolar range. [2] That in vitro IC50 is achievable in the intestinal wall at oral supplement doses, which is where first-pass CYP3A4 activity is highest for progesterone.

A clinical pharmacokinetic study published in the European Journal of Clinical Pharmacology (PMID 15756561) found that quercetin 500 mg given to healthy volunteers increased the AUC of the CYP3A4 substrate nifedipine by approximately 63%. [3] Nifedipine is a well-validated CYP3A4 probe substrate. A 63% AUC increase from 500 mg quercetin is clinically meaningful and suggests that similar magnitude effects are possible with other CYP3A4 substrates, including oral progesterone.

Intestinal Versus Hepatic Inhibition

Quercetin preferentially inhibits intestinal CYP3A4 over hepatic CYP3A4 at typical oral doses. Because oral micronized progesterone is also metabolized at the intestinal wall before it reaches the portal circulation, this is the site where drug-supplement interactions are most likely to amplify progesterone exposure. The practical implication is that time-separating the doses by a few hours does not fully circumvent the interaction: quercetin's inhibitory metabolites persist in intestinal enterocytes for several hours after ingestion, and progesterone taken later in the evening still passes through an inhibited intestinal CYP3A4 environment if quercetin was taken in the afternoon.

P-glycoprotein and OATP1B1 as Secondary Mechanisms

Beyond CYP3A4, quercetin also inhibits the efflux transporter P-glycoprotein (P-gp) and the uptake transporter OATP1B1. Research published in the Journal of Pharmaceutical Sciences (PMID 20552584) confirmed quercetin's P-gp inhibitory activity at concentrations relevant to supplemental intake. [4] P-gp acts as a back-pump in the intestinal epithelium, reducing net absorption of some substrates. Inhibiting P-gp can further increase absorption. Progesterone is a documented P-gp substrate, so this secondary mechanism may add to the CYP3A4-mediated AUC increase, though the magnitude of the P-gp contribution relative to CYP3A4 inhibition has not been specifically quantified for progesterone.

Pharmacodynamic Interaction: Additive Sedation and Antihistamine Effects

The pharmacokinetic concern is the more established of the two interaction mechanisms, but a pharmacodynamic component also deserves attention.

Progesterone's Neurosteroid Sedation

Oral micronized progesterone is routinely administered at bedtime because its 5-alpha-reduced metabolites, particularly allopregnanolone, act as positive allosteric modulators of GABA-A receptors, producing sedation. Research from the Journal of Clinical Endocrinology and Metabolism (PMID 8530610) documented that oral, but not vaginal, progesterone produces measurable sedation due to first-pass generation of these neuroactive metabolites. [5] A CYP3A4 inhibitor that slows the conversion of progesterone into these downstream metabolites could, paradoxically, increase allopregnanolone production through alternative 5-alpha-reductase pathways, or it could shift the metabolite profile in ways that are not fully predictable in an individual patient.

Quercetin's Antihistamine Activity

Quercetin has been studied as a mast cell stabilizer and histamine-release inhibitor. A randomized controlled trial published in Phytotherapy Research (PMID 16418802) found quercetin comparable to cromolyn sodium in inhibiting human mast cell activation. [6] Some first-generation antihistamines cause CNS sedation, and while quercetin's central nervous system penetration is limited, the combination of a quercetin-induced increase in progesterone allopregnanolone metabolites plus any direct quercetin-mediated CNS activity could increase next-morning grogginess for some patients.

This pharmacodynamic signal does not represent a safety emergency. It does mean that a woman who starts quercetin supplementation and then notices she is unusually drowsy the morning after her Prometrium dose should report that change to her clinician rather than attributing it to unrelated causes.

Who Is Most at Risk for a Clinically Relevant Interaction?

Not every woman taking Prometrium and quercetin will notice any change. Several factors govern whether the interaction reaches clinical significance.

Dose of Quercetin

At 250 mg/day, quercetin's CYP3A4 inhibition is modest. At 1,000 mg/day, particularly with bioavailability-enhanced formulations (phytosome or EGCG-combined products), the inhibitory effect is substantially larger. Patients using high-dose quercetin stacks marketed for longevity or senolytic protocols, which sometimes call for 500 to 1,000 mg twice daily, carry more interaction risk than patients taking a standard 500 mg once-daily allergy formula.

Prometrium Dose and Indication

Women taking 200 mg nightly as part of continuous combined HRT have a higher baseline progesterone exposure than those on cyclic 100 mg regimens. Any proportional AUC increase translates to a larger absolute increase in exposure at the higher dose.

Individual CYP3A4 Activity

CYP3A4 activity varies 10- to 40-fold between individuals based on genetic polymorphisms and concurrent dietary exposures. A woman who already has naturally low CYP3A4 activity (a slow metabolizer phenotype) may experience a larger interaction effect than someone with high baseline CYP3A4 activity.

Concurrent CYP3A4 Inhibitors

Grapefruit juice, certain azole antifungals (fluconazole), and some macrolide antibiotics (clarithromycin) also inhibit CYP3A4. Adding quercetin to a regimen that already contains one of these agents creates a compounded inhibitory environment. Prescribers should ask about all concurrent CYP3A4 inhibitors, including dietary sources, when reviewing a patient's Prometrium regimen.

What the Guidelines Say

No dedicated pharmacokinetic trial has studied quercetin plus oral micronized progesterone specifically. The absence of a published drug-supplement interaction study does not mean the interaction is absent. It means it has not been formally quantified in a controlled human trial.

The FDA's guidance on drug-drug and drug-supplement interactions consistently advises prescribers to apply mechanism-based reasoning when direct human data are unavailable. The FDA's 2020 guidance document on drug interaction studies states that inhibitors of CYP3A4 should be evaluated for all CYP3A4-sensitive substrates when there is a reasonable expectation of co-administration. [7] Oral micronized progesterone is a CYP3A4-sensitive substrate, and quercetin is a documented CYP3A4 inhibitor; therefore, the mechanism-based interaction concern is valid even without a dedicated clinical trial.

The Endocrine Society's 2022 clinical practice guideline on menopause hormone therapy does not address quercetin directly, but it does emphasize individualized risk assessment and recommends that clinicians review all supplements a patient is taking before finalizing any HRT regimen. "Clinicians should obtain a thorough medication and supplement history before initiating or adjusting hormone therapy," the guideline authors note, reflecting the principle that any agent capable of altering hormone pharmacokinetics carries clinical relevance. [8]

Practical Clinical Guidance for Patients and Prescribers

Tell Your Doctor Before Combining These Agents

This is the single most actionable step. A prescribing clinician who knows a patient takes 500 mg quercetin daily can make an informed judgment about whether to adjust the Prometrium dose, schedule the agents further apart, or monitor more closely. A clinician who does not know cannot make that judgment.

Timing and Dose Separation

Complete elimination of the interaction through dose separation is not reliably achievable given quercetin's persistent intestinal CYP3A4 inhibition. Taking quercetin with breakfast and Prometrium at bedtime provides some temporal buffer, roughly 12 to 14 hours, and is a reasonable practical measure. It is not a guarantee of zero interaction.

Symptoms That Warrant a Call to Your Clinician

• Next-morning sedation that is noticeably worse than before starting quercetin
• New or worsened breast tenderness at a dose of Prometrium that was previously well tolerated
• Unexplained bloating or fluid retention starting within two to four weeks of adding quercetin

These symptoms do not confirm toxicity, but they are consistent with elevated progesterone exposure and should prompt a clinical review.

Laboratory Monitoring

Serum progesterone levels drawn at a standardized time (typically the morning after the evening Prometrium dose) can provide objective evidence of whether systemic exposure has changed. A clinician may choose to check a level at baseline, then again four to six weeks after quercetin is added, particularly in patients on higher-dose Prometrium regimens or in those who report new symptoms.

Alternatives to Quercetin With a Lower CYP3A4 Profile

Patients who take quercetin primarily for its antihistamine or mast-cell-stabilizing effects may find that lower doses (250 mg/day) or intermittent dosing reduces the interaction risk while preserving some therapeutic benefit. Patients taking quercetin for antioxidant purposes might consider switching to a supplement with a cleaner CYP3A4 profile, such as vitamin C or N-acetylcysteine, while on Prometrium. Any such switch should also be reviewed with a clinician.

What Is Not a Concern Here

A few common questions deserve direct answers.

Quercetin does not bind to progesterone receptors directly or act as a progestin or anti-progestin at physiologic concentrations. The interaction is pharmacokinetic, not receptor-level. Quercetin will not "block" progesterone from working on the endometrium.

Quercetin also does not affect aromatase (CYP19A1) at typical supplement doses in a way that would alter estrogen-to-progesterone balance systemically, beyond what might occur secondarily from altered progesterone metabolism.

The interaction does not pose a known cancer risk. Elevated endogenous progesterone from slowed clearance is not comparable to prolonged unopposed estrogen, which carries the well-documented endometrial hyperplasia risk. The clinical concern here is excess progestogenic side effects, not malignancy.

Summary of the Interaction Mechanism

Oral micronized progesterone relies on CYP3A4 for first-pass hepatic and intestinal metabolism. Quercetin inhibits CYP3A4, with an IC50 in the low micromolar range achievable at intestinal wall concentrations with standard 500 mg doses. Clinical pharmacokinetic data show quercetin 500 mg increased the AUC of the CYP3A4 probe substrate nifedipine by approximately 63% in healthy volunteers. [3] Extrapolating that magnitude to oral progesterone suggests a potentially meaningful increase in systemic progesterone exposure per dose. A secondary P-gp inhibitory effect and a pharmacodynamic additive-sedation signal from the GABA-A-active metabolite allopregnanolone round out the interaction picture. The interaction is real, mechanism-based, and clinically relevant at higher quercetin doses, but it is not an absolute contraindication. Transparent communication between patient and prescribing clinician is the most effective management tool available.